#USA #Chicago #Johnson & Johnson #Head and Neck Cancer #RYBREVANT FASPRO

RYBREVANT FASPRO™ Shows Potential for Advanced Head and Neck Cancer

In the evolving landscape of cancer treatment, Johnson & Johnson has recently brought attention to its promising drug, RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj). The pharmaceutical giant announced pivotal results from the Phase 1b/2 OrigAMI-4 study, which have demonstrated encouraging responses among patients suffering from advanced head and neck squamous cell carcinoma (HNSCC) who had previously undergone other treatments.

The study reports that 42% of the patients in the trial experienced a confirmed overall response rate, with over one-third of these responders achieving complete responses. The median duration of response has not yet been established, but the median follow-up of 11.8 months indicates that responses, when they do occur, can be both strong and durable. These surprising results were presented during an oral session at the prestigious 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and concurrently published in the Journal of Clinical Oncology.

A Key Player in a Challenging Field

HNSCC is among the more aggressive cancer types, significantly affecting quality of life through pain and difficulties associated with common functions like swallowing and speaking. The survival rates for recurrent or metastatic cases are stark; only about 15% of patients survive 5 years post-diagnosis. Existing treatment options have limited efficacy, often peaking at response rates of merely 24%, necessitating new avenues of exploration.

RYBREVANT FASPRO™ occupies a unique position in the treatment space. It is the first subcutaneous therapy being evaluated for this indication that targets both the epidermal growth factor receptor (EGFR) and the mesenchymal-epithelial transition (MET). This dual-targeting approach aims not only to combat tumor growth but also to address issues of resistance that current therapies struggle with. Dr. Barbara Burtness, an oncologist at Yale Cancer Center, remarked on the considerable impact of these findings, noting that previous treatments for recurrent or metastatic HNSCC have yielded very poor outcomes. She emphasized that the durability of responses to RYBREVANT FASPRO™ highlights its potential to improve the landscape of treatment options for these patients.

Analyzing the OrigAMI-4 Results

The OrigAMI-4 study was comprehensive, involving a cohort of 102 patients who received RYBREVANT FASPRO™ as a monotherapy after having undergone other treatment modalities that included immunotherapy and chemotherapy. The results were established through both local assessments by clinical investigators and independent reviews, further bolstering the reliability of the findings. Notably, the treatment-related adverse events were typically mild to moderate and aligned with previous reports associated with EGFR or MET inhibition.

The research indicated a clinical benefit rate of 63%, a median time to first response of 6.6 weeks, and a median progression-free survival of 6.8 months—the latter figures offering hope for patients struggling with limited options. The safety profile appears manageable, with only 8% of patients discontinuing the treatment due to adverse events, a statistic that underscores its potential as a safer alternative compared to existing therapies.

Ongoing Research and Future Directions

Johnson & Johnson is not stopping here. The company has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration (FDA) to seek approval for the use of RYBREVANT FASPRO™ in head and neck cancer treatment, which has been granted Breakthrough Therapy Designation.

Furthermore, there are ongoing studies exploring this treatment in combinations with carboplatin and pembrolizumab in the Phase 3 OrigAMI-5 study, indicating Johnson & Johnson's commitment to potentially redefine how head and neck cancers are treated.

As RYBREVANT FASPRO™ continues to display favorable results, the cancer treatment community remains optimistic about the broader implications of this study for the future of oncology, particularly for patients facing the challenges associated with advanced HNSCC. With more than 40 countries already approving RYBREVANT FASPRO™ for use in treating EGFR-mutated non-small cell lung cancer, its role in the broader oncology landscape is poised for expansion.